{"url_path":"/sec/kalv/8-k/2026-06-11/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","accession_number":"0001140361-26-024949","cik":"0001348911","ticker":"KALV","issuer_name":"KalVista Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","primary_entity_key":"0001348911","primary_entity_name":"KalVista Pharmaceuticals, Inc."},"word_count":214,"has_tables":true,"body_markdown":"Item 3.01\n\nNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\nThe disclosures under the Introductory Note and Item 2.01 are incorporated herein by reference.\n\nOn June 10, 2026, the Company notified the Nasdaq Stock Market LLC (“Nasdaq”) of the anticipated consummation of the Merger and requested that Nasdaq halt trading of the Shares effective as of 8:00 p.m. Eastern Time, on June 10, 2026. On June 11, 2026, the Company (i) notified\nNasdaq of the consummation of the Merger and its intent to remove all Shares from listing on The Nasdaq Global Market and (ii) requested that Nasdaq (A) suspend trading of the Shares and (B) file with the SEC a Form 25 to remove the Shares from\nlisting on The Nasdaq Global Market and deregister the Shares pursuant to Section 12(b) of the Exchange Act.\n\nThe Shares ceased trading on The Nasdaq Global Market effective prior to the opening of trading on June 11, 2026. After effectiveness of the Form 25, the\nCompany intends to file with the SEC a certification and notice of termination on Form 15 to terminate the registration of the Shares under the Exchange Act and suspend the Company’s reporting obligations under Section 13 and Section 15(d) of the\nExchange Act."}